HU Group Holdings Inc. and its wholly owned subsidiary Fujirebio Holdings, Inc. (“Fujirebio”) announced today that Fujirebio’s subsidiary, Fujirebio Diagnostics, Inc., has acquired all of the shares of Plasma Services Group, Inc. (“Plasma Services Group”). The transaction amount was not disclosed.
Founded in 2004, Plasma Services Group is focused on collecting, screening and supplying high-quality rare biological raw materials required for R&D and production in the in vitro diagnostic (IVD) and life science industries, especially in the field of rare diseases. Plasma Services Group has an advanced FDA-registered and ISO-certified facility in Moorestown, New Jersey, USA, providing serum and other samples for control reagents and calibrators for various diseases, and providing sample collection services worldwide. For more information about Plasma Services Group, please visit www.plasmaservicesgroup.com .
Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc., said, “We are pleased to welcome Plasma Services Group to the Fujirebio Group. The company has earned a solid reputation as a reliable global supplier of hard-to-source biological raw materials for the life science industry. Fujirebio and Plasma Services Group’s current and future IVD and life science partners will benefit from the synergy of our joint supply of rare samples and biological raw materials, which in turn further strengthens Fujirebio’s market position as a trusted CDMO partner.”
“For more than 20 years, PSG’s mission has been rooted in serving our clients with care, integrity and a commitment to quality,” said Nichelle Fernandez, President of Plasma Services Group. “This new chapter with Fujirebio is meaningful. It allows us to stay true to who we are while retaining the personalized, responsive service our clients value. By working together, we can provide even greater support to the scientists and innovators who rely on us. Our shared commitment to consistency will have a lasting impact on the global IVD community.”
Advisors
Houlihan Lokey served as exclusive financial advisor to Fujirebio.
Achelous Partners served as exclusive financial advisor to Plasma Services Group.
About Fujirebio
Fujirebio is a global, R&D-driven company developing new technologies and unique biomarkers for in vitro diagnostic tests with high clinical value. The Group’s mission is to create new value in healthcare, thereby contributing to the future of human health and medicine. Our global teams in Japan, Asia, Europe and the United States are focused on delivering products of the highest quality standards to our customers and partners. We value our CDMO partnerships with many of the world’s top diagnostic companies to supply, develop or manufacture diagnostic solutions on multiple platforms by sharing knowledge, capabilities and key materials. For more information about Fujirebio, please visit www.fujirebio.com .
